HARBIN, China, June 24 /PRNewswire-Asia-FirstCall/ -- Renhuang Pharmaceuticals, Inc. (Pink Sheets: RHGP) ("Renhuang" or the "Company"), a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and traditional Chinese medicines ("TCM"), today announced that the Company was recently granted patent protection for its product packaging designs for the Company's Tianma Headache Tablets (in both the 48- and 100-count sizes) and Shengmai Granules by the State Intellectual Property Office of China ("SIPO") of the People's Republic of China.
Design patents are one of three patent categories available under Chinese patent law and are awarded to recognize a unique shape, pattern, or a combination of the two, in an industrial application. A design patent can strengthen brand value by protecting a valuable item of intellectual property (IP).
"We are pleased that the SIPO has awarded us patent protection on three of our packaging designs," said Mr. Shaoming Li, Chairman and Chief Executive Officer of Renhuang. "We have invested significant research and time into developing unique and attractive product packaging designs, resulting in easy market recognition and distinctive features. When consumers see our attractively designed packages, they immediately recognize our brand and know that it contains only the highest quality ingredients and is an all-natural medication. Our move to secure patent protection for our packaging designs is part of our overall intellectual property program as we continue to seek patent security for our proprietary medications, processes and other IP aggressively."
ABOUT RENHUANG PHARMACEUTICALS, INC.
Renhuang Pharmaceuticals, Inc. is engaged in the research, development, manufacturing, and distribution of botanical products, bio-pharmaceutical products, and traditional Chinese medicines ("TCM"), in the People's Republic of China. All of the Company's products are produced at its three GMP-certified production facilities in Ah City, Dongfanghong and Qingyang. The Company distributes its botanical anti-depression and nerve-regulation products, biopharmaceutical products, and botanical antibiotic and OTC TCMs through its network of over 3,000 distributors and over 70 sales centers across 24 provinces in China. Company Website: http://www.renhuang.com .
Safe Harbor Statement
This press release contains certain statements that may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are based upon management's beliefs, assumptions and expectations of the Company's future operations and economic performance, taking into account the information currently available to management. These statements are not statements of historical fact. Forward-looking statements involve risks and uncertainties, some of which are not currently known that may cause actual results, performance or financial condition to be materially different from the expectations of future results, performance or financial condition expressed or implied in any forward-looking statements. These forward-looking statements are based on current plans and expectations and are subject to a number of uncertainties including, but not limited to, the Company's ability to secure adequate patent protection for its medications, processes and other IP, the Company's perceived benefits of patent protection for its packaging designs, ability to manage expansion of its operations effectively, and other factors detailed in the Company's annual report on Form 10-K and other filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented herein.
For more information, please contact: Renhuang Pharmaceuticals, Inc. Ms. Portia Tan, IR Contact Phone: +86-451-8260-2162 Email: firstname.lastname@example.org CCG Investor Relations: Mr. Mark Collinson, Partner Phone: +1-310-954-1343 (Los Angeles) Email: email@example.com Web: http://www.ccgirasia.com Mr. Crocker Coulson, President Phone: +1-646-213-1915 (New York) Email: firstname.lastname@example.org
SOURCE Renhuang Pharmaceuticals, Inc.